US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

17.17

-0.2900-1.66%

Post-market: 17.170.00000.00%19:30 EDT

Volume:436.83K

Turnover:7.57M

Market Cap:2.22B

PE:-7.62

High:17.96

Open:17.52

Low:17.00

Close:17.46

52wk High:28.23

52wk Low:16.39

Shares:129.54M

Float Shares:44.92M

Volume Ratio:0.45

T/O Rate:0.97%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.99

PE(LYR):0.00

Loading ...

Overview Company News Filings

Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate

Benzinga Earnings

Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million

Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027

THOMSON REUTERS

Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027

THOMSON REUTERS

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS

Kailera Therapeutics Names Nur Nicholson Chief Technology Officer

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

THOMSON REUTERS

Kailera Therapeutics Inc Expected to Post a Loss of 75 Cents a Share - Earnings Preview

Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning

Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)

Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Wall Street Analysts Are Bullish on Top Healthcare Picks

Kailera Therapeutics announces positive Phase 3 data for weight loss drug

Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China

THOMSON REUTERS

Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success

Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/KLRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":17.17,"timestamp":1787342400000,"preClose":17.46,"halted":0,"volume":436830,"hourTrading":{"tag":"盘后","latestPrice":17.17,"preClose":17.17,"latestTime":"19:30 EDT","volume":2129,"amount":36551.25,"timestamp":1787355007970,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.016609392898052643,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Market Closed","change":-0.29,"latestTime":"08-21 16:00:00 EDT","open":17.52,"high":17.96,"low":17,"amount":7570552.207800001,"amplitude":0.054983,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":17.46,"preHourTrading":{"tag":"盘前","latestPrice":17.8,"preClose":17.46,"latestTime":"08:04 EDT","volume":12,"amount":213.55998,"timestamp":1787313854187,"change":0.34,"changeRate":0.019473,"amplitude":0.028637},"postHourTrading":{"tag":"盘后","latestPrice":17.17,"preClose":17.17,"latestTime":"19:30 EDT","volume":2129,"amount":36551.25,"timestamp":1787355007970,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4456496744289272},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":0.4456496744289272,"shares":129537300,"dividePrice":0,"high":17.96,"amplitude":0.054983,"preClose":17.46,"low":17,"week52Low":16.39,"pbRate":"1.99","week52High":28.2271,"institutionHeld":0,"latestPrice":17.17,"eps":-2.254252,"divideRate":0,"volume":436830,"delay":0,"ttmEps":-2.254252,"open":17.52,"prevYearClose":16,"prevWeekClose":17.94,"prevMonthClose":16.94,"prevQuarterClose":22.03,"fiveDayClose":17.94,"twentyDayClose":17.69,"sixtyDayClose":21.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-08-21","current":-7.616717,"percent":1,"low":-21.871461,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"high":-7.746755,"avg":-15.438559,"sd":4.169763,"marketCap":2263578582},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582}],"updateTime":1787522447739},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659818171","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659818171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659818171?lang=en_us&edition=fundamental","pubTime":"2026-08-13 08:10","pubTimestamp":1786579809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on P3 Health Partners (PIII) and Kailera Therapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-p3-health-partners-piii-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-p3-health-partners-piii-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PIII","LU0029874061.USD","BK4585","BK4139","BK4196","LU0128526141.USD","BK4588","BK4581","KLRA","OZEM","HCSG","XLV","XBI","LABU","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659850186","title":"Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659850186","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659850186?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:22","pubTimestamp":1786573367,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryKailera Therapeutics IncKLRA.OQreported a quarterly adjusted loss of $1.09 per share for the quarter ended June","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4492B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188516","title":"Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188516","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188516?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:39","pubTimestamp":1786567145,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61160351/kailera-therapeutics-q2-eps-1-09-misses-0-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659074999","title":"Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659074999","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659074999?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565148,"startTime":"0","endTime":"0","summary":"Kailera Q2 FY26 net loss widens to $111.31 million; R&D expenses climb to $101.06 millionKailera posted a net loss of USD 111.31 million, widening from USD 28.95 million a year earlier.R&D expenses mo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbzlZ13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4112","BCDF","NDAQ","BK4139","OZEM","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659670188","title":"Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659670188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659670188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659605188","title":"Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659605188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659605188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659290711","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659290711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659290711?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992804","title":"Kailera Therapeutics Names Nur Nicholson Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992804","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992804?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:05","pubTimestamp":1786446310,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics names Nur Nicholson chief technology officerKailera Therapeutics named Nur Nicholson chief technology officer, effective Aug. 31, 2026.Role centers on scaling manufacturing and su","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL2PFshn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4112","BK4533","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","BCDF","PBE","OZEM","LU0109394709.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","LU0320765992.SGD","LU0234570918.USD","SG9999014039.USD","KLRA","SG9999014021.USD","BK4588","IE00B3QW5Z07.USD","LU0889565916.HKD","NDAQ","IE00B894F039.SGD","LU2210150020.SGD","IE00B19Z9P08.USD","LU2210149790.SGD","BK4139","IE00BKPKM429.USD","BK4532","BIIB","LU2095319765.USD","SG9999014005.SGD","IE00B19Z9Z06.USD","BMED","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999445","title":"Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999445","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658999445?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAC13XLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957199","title":"Kailera Therapeutics Inc Expected to Post a Loss of 75 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957199","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957199?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:27","pubTimestamp":1786400825,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics Inc <KLRA.OQ> expected to post a loss of75cents a share - Earnings PreviewKailera Therapeutics IncKLRA.OQKLRA.Ois expected to  report resultson August 12 for the period ending Jun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44727M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126637747","title":"Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1126637747","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126637747?lang=en_us&edition=fundamental","pubTime":"2026-08-05 10:27","pubTimestamp":1785896846,"startTime":"0","endTime":"0","summary":"Abstract Kailera Therapeutics will report fiscal results on August 12, 2026 Post-Mkt, with the market looking for zero revenue, a forecast adjusted EPS of -0.75, and EBIT of -120.50 million US...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650152659","title":"Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning","url":"https://stock-news.laohu8.com/highlight/detail?id=2650152659","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650152659?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:16","pubTimestamp":1783541765,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics files Form 3 for Chief Corporate Affairs Officer Kathleen TregoningKailera Therapeutics named Kathleen Tregoning as chief corporate affairs officer in an initial Form 3 filing dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL8l21D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OZEM","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649099976","title":"Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649099976","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649099976?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:35","pubTimestamp":1783517747,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Kailera Therapeutics, Inc., with a price target of $48.00. Song co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649346689","title":"Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649346689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649346689?lang=en_us&edition=fundamental","pubTime":"2026-07-08 01:30","pubTimestamp":1783445416,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA). A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4588","KLRA","BK4585","BK4139","OZEM","BK4185","XLV","LABU","ACHC","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649402939","title":"Race to Launch Weight-loss Pills Heats up as Smaller Players Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2649402939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649402939?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:12","pubTimestamp":1783440755,"startTime":"0","endTime":"0","summary":"FACTBOX-Race to launch weight-loss pills heats up as smaller players advanceAdds details of Kailera Therapeutics' obesity drug in paragraphs 1,2 and 25July 7 (Reuters)-Kailera Therapeutics'KLRA.Ooral ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4391DU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014898.SGD","IE00BWXC8680.SGD","AGNG","LU1066051811.HKD","LU2023251221.USD","LU1069344957.HKD","LU2491050071.SGD","LU0708995401.HKD","LU0133085943.USD","LU0708994859.HKD","LU1989772923.USD","LU0882574055.USD","IE00B19Z3581.USD","LU2106854487.HKD","RXL","LU0158827781.USD","LU0114720955.EUR","LU0321505439.SGD","LU0130102774.USD","IE00BLSP4239.USD","LU2125154935.USD","LU1883839398.USD","LLY","LU2237443382.USD","LU0130517989.USD","LU2552382215.SGD","NVOX","LU2023250504.SGD","LU0471298694.HKD","LU1127390331.HKD","IE00BZ1G4Q59.USD","LU1035773651.USD","SG9999015978.USD","LU2433249047.HKD","LU0225283273.USD","LU2750360641.GBP","IXJ","LU0211331839.USD","SG9999002224.SGD","LU1868837136.USD","IYH","LU2756315318.SGD","LU2168564495.EUR","LU0683600562.USD","LU1868836757.USD","LU0289739699.SGD","LU2264538146.SGD","LU2237443978.SGD","LU0353189680.USD","LU1551013425.SGD","LU1941712348.USD","BK4588","LU1934455863.HKD","LU1868837300.USD","LLYX","SG9999014906.USD","LU0477156953.USD","LU2023250843.SGD","IE00B7KXQ091.USD","LU1066051498.USD","MEDX","LU2097828714.EUR","LU1037948897.HKD","LU1804176565.USD","LU2087625088.SGD","LU2357627491.SGD","KLRA","SG9999014542.SGD","FHLC","LU2168564222.USD","SG9999014914.USD","LU2417539215.USD","IE00B19Z3B42.SGD","LU1116320737.USD","LU0094547139.USD","LU2089283258.USD","LU0820561909.HKD","LU0306806265.USD","LU2324357040.USD","LU2125909247.SGD","LU2756315664.SGD","LU0640476718.USD","LU0965509101.SGD","LU1712237335.SGD","NVO","LU0208291251.USD","IE000M9KFDE8.USD","LU0310800379.SGD","LU0455707207.USD","IE00BKDWB100.SGD","LU0203345920.USD","LU1116320901.HKD","SG9999001440.SGD","XLV","IE00BLSP4452.SGD","JDOC","LU0859254822.USD","LU0320765992.SGD","IE00BJJMRX11.SGD","LU0320765489.SGD","LU2089984988.USD","LU0823416689.USD","WDNA","LU0345770308.USD","LU1551013342.USD","IE00BK4W5M84.HKD","LU2360032135.SGD","IE00BSNM7G36.USD","LU0471298777.SGD","LU1868836914.USD","LU2108987350.USD","LU1623119135.USD","SG9999018857.SGD","01801","LU2602419157.SGD","NVOH","LU0109394709.USD","LU0203202063.USD","LU0316494557.USD","LU1066051225.USD","LU2360106947.USD","LU0097036916.USD","LU1267930573.SGD","LU0170899867.USD","LU0203347892.USD","LU0203201768.USD","LU1814569148.SGD","LU0061475181.USD","ELIL","LU2097828474.EUR","LU2462157665.USD","IE00B1BXHZ80.USD","LU0648001328.SGD","LU0122379950.USD","LU0823434583.USD","LU2089284900.SGD","SG9999001176.SGD","LU2063271972.USD","LU0964807845.USD","LU1923622614.USD","LU2097828557.USD","LU1868836591.USD","LU0128525929.USD","LU2237443622.USD","LU2361044865.SGD","LU0868494708.USD","VKTX","LU2236285917.USD","LU2552382058.USD","PAWZ","SG9999015945.SGD","BK4592","LU0198837287.USD","SGXZ57979304.SGD","LU1699723380.USD","BK1589","LU1093756325.SGD","LU2237443549.SGD","LU2213496289.HKD","LU0006306889.USD","LU0502904849.HKD","LU0320765059.SGD","LU2468319806.SGD","BK4533","LU0861579265.USD","SGXZ99366536.SGD","GB00BDT5M118.USD","VHT","LU2211815571.USD","SG9999001176.USD","LU1291159041.SGD","LU2237438978.USD","LU1894683348.USD","LU0320765646.SGD","LU0238689110.USD","LU0432979614.USD","LU0985481810.HKD","AZNH","PFE","LU0256863902.USD","BK4007","LU1069347547.HKD","01672","IE00BJJMRY28.SGD","LU0058720904.USD","LU0889565916.HKD","LU1064131342.USD","LU2125909593.SGD","LU2237443895.HKD","LU2456880835.USD","SG9999015986.USD","LU2111349929.HKD","SG9999015952.SGD","LU1629891620.HKD","IE00B3T34201.USD","LU2237443465.HKD","BK4568","LU1974910355.USD","LU1037948541.HKD","IE0004445015.USD","LU2471134879.HKD","LLYZ","LU0943347566.SGD","PPH","LU0070302665.USD","LU0321505868.SGD","LU1093756168.USD","LU2471134952.CNY","LU1323610961.USD","LU0345770993.USD","KURE","LU0354030438.USD","IE00BKPKM429.USD","ILDR","LU1061106388.HKD","CANC","BK4581","IE00BFTCPJ56.SGD","LU0210536198.USD","LU2168564149.EUR","LU0266013472.USD","LU2271345857.HKD","LU1989771016.USD","LU2097828805.USD","LU2168563687.JPY","SG9999014575.USD","CURE","BMED","LU2328871848.SGD","LU2265009873.SGD","LU2552382132.HKD","BK4559","LU2471134523.USD","HRTS","PJP","BK4599","GPCR","LU0672654240.SGD","LU2491049909.HKD","SG9999017495.SGD","LU0306807586.USD","LU0417517546.SGD","BK4532","LU0096364046.USD","LU1366192091.USD","IE00BBT3K403.USD","LU0965508806.USD","SGXZ81514606.USD","LU2746668974.SGD","BK4585","LU1571399168.USD","LU0820561818.USD","LU2488822045.USD","LU2461242641.AUD","LU1720051108.HKD","BK4516","LU0079474960.USD","LU1430594728.SGD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1548497426.USD","IE00BJLML261.HKD","LU1829250122.USD","LU1280957306.USD","SG9999011175.SGD","LU1941712264.USD","AZN","LU2125154778.USD","IE0002141913.USD","IE0005OL40V9.USD","BK1161","LU0234572021.USD","LU0868494617.USD","MEDI","LU0106261372.USD","LU0787776722.HKD","LU1585245621.USD","BK1515","SGXZ51526630.SGD","LU0265550946.USD","LU0385154629.USD","IE00BKVL7J92.USD","LU2028103732.USD","OZEM","LU2491050154.USD","LU0323591593.USD","LU2361045086.USD","LU1989772840.SGD","LU1917777945.USD","LU1934455277.USD","IE00B1XK9C88.USD","LU1267930730.SGD","LU0109391861.USD","SG9999014567.USD","SG9999014880.SGD","LU0942090050.USD","LU0353189763.USD","LU1983299246.USD","LU0823434740.USD","LU1894683264.USD","LU0965509283.SGD","LU1969619763.USD","LU0158827948.USD","BK4534","LU0029864427.USD","LU0689472784.USD","LU1145028129.USD","LU1988902786.USD","LU2746668461.USD","LU0820562030.AUD","LU2357305700.SGD","LLII","LU0882574139.USD","LU2097828631.EUR","ELIS","LU0265550359.USD","LU0985320562.USD","LU0154236417.USD","SGXZ31699556.SGD","THNR","LU1023059063.AUD","LU0466842654.USD","SG9999002232.USD","IE00B4R5TH58.HKD","SG9999015341.SGD","LU0225771236.USD","LU1232071149.USD","LU2750360997.AUD","LU1201861249.SGD","LU2112291526.USD","IE00BN29S564.USD","IE0004445239.USD","LU2168564065.EUR","IE00BK4W5L77.USD","SG9999015358.SGD","LU2242644610.SGD","LU2896262040.SGD","IE00BJT1NW94.SGD","LU0354030511.USD","LU2471134796.USD","LU1162221912.USD","IE0002270589.USD","IE00BFSS8Q28.SGD","HK0000165453.HKD","MRK","IHE","BK4139","SG9999018865.SGD","IE00B4JS1V06.HKD","IE00B775H168.HKD","LU1057294990.SGD","BK4550","LU2361044949.HKD","LU0980610538.SGD","LU0256863811.USD","LU1929549753.HKD","IE00BFSS7M15.SGD","LU1035775433.USD","LU2596442595.SGD","LU0456855351.SGD","BK1583","IE00B2B36J28.USD","IE0001KFT4U8.USD","IE0009355771.USD","LU1934455194.USD","SG9999013999.USD","LU0965509010.AUD","LU0098860793.USD","LU2023250330.USD","FTXH","LU0225284248.USD","LU1720051017.SGD","SG9999003800.SGD","LU0786609619.USD","IE00BN8TJ469.HKD","GDOC","SG9999014559.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649352259","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2649352259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649352259?lang=en_us&edition=fundamental","pubTime":"2026-07-07 22:40","pubTimestamp":1783435211,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kailera Therapeutics, Inc. (KLRA) and Revolution Med...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-246?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-246?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649933246","title":"Kailera Therapeutics announces positive Phase 3 data for weight loss drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2649933246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649933246?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:35","pubTimestamp":1783431310,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA) announced positive topline results from two Phase 3 clinical trials conducted by its partner, Hengrui Pharma, evaluatin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-phase-3-data-for-weight-loss-drug-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-phase-3-data-for-weight-loss-drug-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","KLRA","BMED","HYLG","MEDX","GDOC","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984022","title":"Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984022?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:31","pubTimestamp":1783423890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OZEM","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649162984","title":"Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2649162984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649162984?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:21","pubTimestamp":1783423300,"startTime":"0","endTime":"0","summary":"UPDATE 3-Kailera shares tumble on high nausea rates despite weight-loss drug's successJuly 7 (Reuters)-Kailera Therapeutics'KLRA.Oshares dropped 10% on Tuesday after its oral weight-loss drug showed h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4390VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211326839.USD","LU2089284900.SGD","600276","LU2097828805.USD","LU0310799852.SGD","LU0960981461.USD","LU2293690249.USD","LU1267930813.SGD","LU0972486137.USD","LU1328615791.USD","LU0266013472.USD","LU1273509221.SGD","LU0526926950.USD","LU1046234339.USD","LU1267930227.SGD","LU2097828631.EUR","LU1481600234.SGD","SGXZ57979304.SGD","LU0289739699.SGD","LU1781817850.SGD","LU2097828557.USD","LU2324357040.USD","LU0889566641.SGD","LU0345777659.USD","LU0976567544.SGD","LU0203345920.USD","LU0171276677.USD","IE00B4R5TH58.HKD","AZN.UK","LU2237443549.SGD","LU2237443622.USD","03165","LU0784384876.USD","BK0188","LU0957799991.USD","LU1146622755.USD","LU0949170426.SGD","LU2237443978.SGD","LU0310800965.SGD","LU1078025761.USD","LU1989771016.USD","IE0034235188.USD","KLRA","LU1064130708.USD","SG9999001176.USD","LU0496365809.HKD","OZEM","LU0405327494.USD","LU0211327993.USD","LU1880407215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984887","title":"Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984887?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:06","pubTimestamp":1783422405,"startTime":"0","endTime":"0","summary":"Kailera's GLP-1 drug meets main goal of late-stage trialsJuly 7 (Reuters)-Kailera TherapeuticsKLRA.Osaid on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4390VA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":79,"code":"91000000","status":"200"}]}}